Literature DB >> 8386033

Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.

B Weber1, W Braun, J Cinatl, H W Doerr.   

Abstract

For the development of effective prophylaxis (hyperimmune globulins) and improvement of serological testing for human cytomegalovirus (HCMV) infection in immunocompromised patients it is essential to characterize the viral encoded proteins and the humoral immune response in terms of neutralizing antibodies and immunoglobulin class and IgG subclass reactivity to "early" and "late" HCMV proteins. The major neutralizing epitopes have been identified and screening of donor sera for neutralizing antibody by either conventional neutralization assays or enzyme-linked immunosorbent assay using recombinant antigens may help to improve the efficacy of hyperimmune globulin prophylaxis. The humoral response to individual HCMV proteins has been thoroughly investigated in immunocompromised patients. Antibodies against HCMV induced "early" antigens are not exclusively associated with active infection but may indicate an elevated risk for cytomegalic inclusion disease in immunocompromised patients. With a sensitive western blot technique. IgM and IgA antibodies against HCMV "late" proteins can be detected in sera from healthy seropositive individuals. Serum samples from subjects suffering from cytomegalic inclusion disease show significantly larger broader immune responses compared with healthy HCMV antibody carriers. Promising results using recombinant antigens corresponding to immunodominant epitopes for the detection of HCMV specific antibodies have been published.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386033     DOI: 10.1007/bf00184725

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  65 in total

1.  Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients.

Authors:  S W Chou
Journal:  J Infect Dis       Date:  1989-07       Impact factor: 5.226

2.  IgG subclass-specific antibodies to human cytomegalovirus (HCMV)-induced early antigens.

Authors:  A Hamann; H W Doerr
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

3.  Modified diffusion blotting for rapid and efficient protein transfer with PhastSystem.

Authors:  W Braun; R Abraham
Journal:  Electrophoresis       Date:  1989-04       Impact factor: 3.535

4.  The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties.

Authors:  G Jahn; B C Scholl; B Traupe; B Fleckenstein
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

5.  Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients.

Authors:  J A Zaia; S J Forman; Y P Ting; E Vanderwal-Urbina; K G Blume
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

6.  Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals.

Authors:  M A McVoy; S P Adler
Journal:  J Infect Dis       Date:  1989-07       Impact factor: 5.226

7.  Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera.

Authors:  L Pereira; M Hoffman; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

8.  IgG-subclass-specific CMV reactivity in bone marrow transplant recipients.

Authors:  B Wahren; A Linde; V A Sundqvist; P Ljungman; B Lönnqvist; O Ringdén
Journal:  Transplantation       Date:  1984-11       Impact factor: 4.939

9.  Comparison of shell viral culture and serology for the diagnosis of human cytomegalovirus infection in neonates and immunocompromised subjects.

Authors:  B Weber; A Hamann; B Ritt; H Rabenau; W Braun; H W Doerr
Journal:  Clin Investig       Date:  1992-06

10.  Antibodies to human cytomegalovirus structural polypeptides during primary infection.

Authors:  M P Landini; E Rossier; H Schmitz
Journal:  J Virol Methods       Date:  1988-12       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.